Fate Therapeutics (NASDAQ:FATE) Price Target Cut to $5.00 by Analysts at Cantor Fitzgerald

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price target trimmed by Cantor Fitzgerald from $8.00 to $5.00 in a research report report published on Thursday, The Fly reports. Several other brokerages have also issued reports on FATE. Morgan Stanley cut their price target on Fate Therapeutics from $35.00 to $8.00 and set an equal […]

Related Keywords

Philip Beachy ,Leonard Zon ,Rudolf Jaenisch ,David Scadden ,Alexander Rives ,Scott Wolchko ,Michael Rudnicki ,Citigroup ,Morgan Stanley ,Nisa Investment Advisors ,Coppell Advisory Solutions Corp ,Ci Investments Inc ,Fate Therapeutics Inc ,Cantor Fitzgerald ,Managers Group ,Redmile Group Llc ,Fate Therapeutics ,Get Rating ,Director Redmile Group ,Investment Advisors ,Coppell Advisory Solutions ,Sheng Ding ,Fate Therapeutics Daily ,Nasdaq Fate ,Fate ,Medical ,Lower Price Target ,